TBC1D22B

Across TCGA pan-cancer cohorts, TBC1D22B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TBC1D22B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TBC1D22B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TBC1D22B is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where TBC1D22B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D22B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.452	<.001	12	view →
HNSC	Female	All	−0.360	<.001	11	view →
LUAD	Female	All	+0.204	<.001	7	view →
PDAC	All	All	−0.271	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TBC1D22B–CCRCC

Open the CCRCC breakdown →